Specific biomarkers of receptors, pathways of inhibition and targeted therapies: Pre-clinical developments

British Journal of Radiology

Volumn 84, Issue SPEC. ISSUE 2, 2011, Pages

  Waerzeggers, Y ^a   Monfared, P ^b   Viel, T ^a   Faust, A ^a   Kopka, K ^a   Schafers M ^a   Tavitian, B ^c   Winkeler, A ^c   Jacobs, A ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; LIPOCORTIN 5; MEMBRANE RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SYNAPTOTAGMIN I; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; APOPTOSIS REGULATORY PROTEIN; TUMOR MARKER; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDIOVASCULAR FUNCTION; CELL DEATH; DNA METABOLISM; DRUG SCREENING; ENERGY; GENETIC DISORDER; GLIOBLASTOMA; HUMAN; HYPOXIA; ISOTOPE LABELING; MOLECULAR GENETICS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; GLIOMA; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); REGULATORY SEQUENCE; REVIEW;

ANIMALS; ANNEXIN A5; APOPTOSIS REGULATORY PROTEINS; BRAIN NEOPLASMS; GLIOMA; HUMANS; INTEGRINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; REGULATORY ELEMENTS, TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; SYNAPTOTAGMIN I; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867207311     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/66405626     Document Type: Article

References (109)

1. Schaller BJ, Modo M, Buchfelder M. Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol Imaging Biol 2007;9:60-71. (Pubitemid 46336220)
2. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9. (Pubitemid 39330996)
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53. (Pubitemid 47339290)
4. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 2007;19:598-605.
5. De Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Curr Opin Neurol 2007;20:712-18. (Pubitemid 350085016)
6. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. (Pubitemid 46075199)
7. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epider-mal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64: 5355-62. (Pubitemid 39006556)
8. Norden AD, Wen PY. Glioma therapy in adults. Neuro-logist 2006;12:279-92. (Pubitemid 44813664)
9. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-16. (Pubitemid 28406817)
10. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127-37. (Pubitemid 29009842)
11. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med 2008;49(Suppl. 2):81S-95S. (Pubitemid 351948038)
12. Zhou D, Chu W, Rothfuss J, Zeng C, Xu J, Jones L, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 2006;16:5041-6. (Pubitemid 44247712)
13. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, et al. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 2002;99:16551-5. (Pubitemid 36034010)
14. Bullok K, Piwnica-Worms D. Synthesis and characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J Med Chem 2005;48:5404-7 (Pubitemid 41209236)
15. Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004;6:95-105. (Pubitemid 38544597)
16. Neves AA, Brindle KM. Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 2006;1766:242-61.
17. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182:1545-56.
18. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998;95:6349-54. (Pubitemid 28249015)
19. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-74. (Pubitemid 35025718)
20. Kartachova M, Haas RL, Olmos RA, Hoebers FJ, van Zandwijk N, Verheij M. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 2004;72:333-9. (Pubitemid 39265388)
21. Belhocine T, Steinmetz N, Li C, Green A, Blankenberg FG The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol Cancer Res Treat 2004;3:23-32. (Pubitemid 38250465)
22. Lahorte CM, van de Wiele C, Bacher K, van den Bossche B, Thierens H, van Belle S, et al. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans. Nucl Med Commun 2003;24:871-80.
23. Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, et al. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 2004;15:373-9. (Pubitemid 38365198)
24. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, et al. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004; 31:469-74. (Pubitemid 38461560)
25. Keen HG, Dekker BA, Disley L, Hastings D, Lyons S, Reader AJ, et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 2005;32:395-402. (Pubitemid 40692689)
26. Cauchon N, Langlois R, Rousseau JA, Tessier G, Cadorette J, Lecomte R, et al. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphati-dylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging 2007;34:247-58. (Pubitemid 46147508)
27. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2:303-12.
28. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A, Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003;63:1936-42. (Pubitemid 36460861)
29. Schellenberger EA, Bogdanov A, Jr., Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging 2002;1:102-7
30. Hiller KH, Waller C, Nahrendorf M, Bauer WR, Jakob PM. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging 2006;5:115-21. (Pubitemid 44106146)
31. Van Tilborg GA, Mulder WJ, Deckers N, Storm G, Reute-lingsperger CP, Strijkers GJ, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem 2006;17:741-9. (Pubitemid 43794385)
32. Van Tilborg GA, Mulder WJ, Chin PT, Storm G, Reutelingsperger CP, Nicolay K, et al. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem 2006;17:865-8. (Pubitemid 44162601)
33. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001;7:1241-4. (Pubitemid 33063780)
34. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 2008;62: 31-50; discussion 50-2. (Pubitemid 351640237)
35. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004;70:229-43. (Pubitemid 39545734)
36. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000;48:571-82.
37. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33. (Pubitemid 32336342)
38. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004;64:6101-8. (Pubitemid 39129410)
39. Semenza GL. HIF-1: mediator of physiological and patho-physiological responses to hypoxia. J Appl Physiol 2000; 88:1474-80. (Pubitemid 30217451)
40. Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008;8:301-14. (Pubitemid 351724709)
41. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9. (Pubitemid 46424067)
42. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007;6:1909-19. (Pubitemid 47052481)
43. Cai W, Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci 2007;12:4267-79.
44. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49 Suppl 2:113S-28S. (Pubitemid 351948040)
45. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, et al. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radia-tion dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging 2004;48:198-206. (Pubitemid 39485387)
46. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006;6:407-28. (Pubitemid 44377776)
47. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006;47:2048-56. (Pubitemid 47544993)
48. Chan C, Sandhu J, Guha A, Scollard DA, Wang J, Chen P, et al. A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. J Nucl Med 2005;46:1745-52. (Pubitemid 46211599)
49. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313-19. (Pubitemid 47242797)
50. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al. Molecular imaging and biological evalua-tion of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93. (Pubitemid 35251753)
51. Korpanty G, Grayburn PA, Shohet RV, Brekken RA. Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 2005;31:1279-83. (Pubitemid 41318861)
52. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz AM, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endo thelial growth factor receptor type 2 in mice. Radiology 2008;246:508-18.
53. Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, et al. Multimodality molecular imaging of glioblas-toma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007;48:445-54. (Pubitemid 47604931)
54. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87. (Pubitemid 35283958)
55. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8. (Pubitemid 46797938)
56. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100. (Pubitemid 37328796)
57. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003;3:659-71. (Pubitemid 37236408)
58. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 2006;47:113-21.
59. Cao Q, Cai W, Li ZB, Chen K, He L, Li HC, et al. PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 2007;34:1832-42. (Pubitemid 47599047)
60. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5. (Pubitemid 32691983)
61. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emis-sion tomography and [18F]Galacto-RGD. PLoS Med 2005; 2:e70.
62. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6. (Pubitemid 28237365)
63. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63:5838-43. (Pubitemid 37187482)
64. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, et al. Magnetic resonance molecular imaging with nanoparticles. J Nucl Cardiol 2004;11:733-43. (Pubitemid 40012045)
65. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, et al. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006;8:315-23. (Pubitemid 44741368)
66. Xiong Z, Cheng Z, Zhang X, Patel M, Wu JC, Gambhir SS, et al. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 2006;47:130-9. (Pubitemid 46768522)
67. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80. (Pubitemid 28063372)
68. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12:6677-86. (Pubitemid 44876835)
69. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 2005;19:2008-10. (Pubitemid 41759747)
70. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 2007;21:378-83. (Pubitemid 46213485)
71. Jin ZH, Razkin J, Josserand V, Boturyn D, Grichine A, Texier I, et al. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Mol Imaging 2007;6: 43-55. (Pubitemid 46642490)
72. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006;5:2624-33. (Pubitemid 44848989)
73. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor ima-ging. Mol Pharm 2006;3:472-87. (Pubitemid 44639125)
74. Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman L. ICAM-1 expression in autoimmune encep-halitis visualized using magnetic resonance imaging. J Neuroimmunol 2000;104:1-9. (Pubitemid 30100884)
75. Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA, Jr. Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest 2006;86:599-609. (Pubitemid 43780441)
76. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005;105:420-5. (Pubitemid 40053114)
77. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 2003;10:647-56. (Pubitemid 36553610)
78. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA 2001; 98:9300-5. (Pubitemid 32743911)
79. Xu H, el-Gewely MR. P53-responsive genes and the potential for cancer diagnostics and therapeutics develop-ment. Biotechnol Annu Rev 2001;7:131-64. (Pubitemid 41081527)
80. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 2003;9:4884-90. (Pubitemid 37323294)
81. Monfared P, Winkeler A, Klein M, Li H, Klose A, Hoesel M, et al. Noninvasive assessment of E2F-1-mediated transcrip-tional regulation in vivo. Cancer Res 2008;68:5932-40.
82. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 2008;35:186-208. (Pubitemid 350234146)
83. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003;30:3-14. (Pubitemid 36828623)
84. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70. (Pubitemid 37322983)
85. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-9.
86. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996;13:85-96. (Pubitemid 26248548)
87. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
88. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 2008;14:957-60. (Pubitemid 351302539)
89. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32A:636-40.
90. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42. (Pubitemid 41095125)
91. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007;96:1047-51. (Pubitemid 46608313)
92. Preusser M, Gelpi E, Rottenfusser A, Dieckmann K, Widhalm G, Dietrich W, et al. Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progres-sive high grade glioma: an exploratory study. J Neurooncol 2008;89:211-18.
93. Van Den Bent MJ, Brandes A, Rampling R. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. J Clin Oncol (Meeting Abstracts) 2007 (25):2005.
94. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7. (Pubitemid 41417939)
95. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24. (Pubitemid 41609094)
96. Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev 2008;27:645-53.
97. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8:262-77. (Pubitemid 44446020)
98. Carlsson J, Gedda L, Gronvik C, Hartman T, Lindstrom A, Lindstrom P, et al. Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys 1994;30:105-15. (Pubitemid 24291120)
99. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005;46:1881-8. (Pubitemid 46196651)
100. Cornelissen B, Kersemans V, Burvenich I, Oltenfreiter R, Vanderheyden JL, Boerman O, et al. Synthesis, bio-distribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor. Nucl Med Commun 2005; 26:147-53. (Pubitemid 40271200)
101. Cuartero-Plaza A, Martinez-Miralles E, Rosell R, Vadell-Nadal C, Farre M, Real FX. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 1996;2:13-20.
102. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850-8. (Pubitemid 46798960)
103. Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 1998;75: 626-34. (Pubitemid 28094112)
104. Diagaradjane P, Orenstein-Cardona JM, N EC-C, Deorukhkar A, Shentu S, Kuno N, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731-41. (Pubitemid 351231154)
105. Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, et al. Molecular imaging of Akt kinase activity. Nat Med 2007;13:1114-19. (Pubitemid 47517501)
106. Li W, Li F, Huang Q, Frederick B, Bao S, Li CY. Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer Res 2008;68:4990-7.
107. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63. (Pubitemid 28479189)
108. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41. (Pubitemid 40705010)
109. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006;5:2991-3000. (Pubitemid 46092040)